jj agre 25bn guidant dealpharmaceut giant johnson  johnson agre buy medic technolog firm guidant 254bn 13bnguidant key produc equip combat heart problem implant defibril pacemak analyst said deal aim offset johnson  johnson relianc slow drug busi also point merger like drug healthcar industri fragment pressur cut cost number johnson  johnson product face patent expir compani also battl fierc competit generic product meanwhil demand defibril give heart small electr shock irregular heartbeat rhythm detect expect increas analyst said move johnson  johnson wide expect firm will pay 76 guidant share 6 wednesday close price analyst say us antitrust regul forc firm overlap stent oper stent tube use keep arteri open unblock